Normax Biomed Ltd (Normax) is based in Cork, Ireland, and London, England. Normax is in the business of mRNA vaccine Research, Development and Manufacturing. Normax has secured a €300,000,000 capital commitment from a $3.4Bn cornerstone institutional investor for development of mRNA Vaccines and Vax Factory Manufacturing for Transformative Social Impact on Infectious Disease and Pandemic Preparedness. Normax plans to drive down the cost of mRNA Vaccines to save more lives and to deliver sustainable returns for impact investors. Normax plans to deliver safe and effective mRNA vaccines at large scale for about $4 dollars per dose. Normax mRNA vaccine products in development include: (1) mRNA Vax Factory, (2) Universal Coronavirus mRNA Vaccine, (3) Tuberculosis mRNA Vaccine, (4) HIV mRNA Vaccine, (5) Malaria mRNA Vaccine, and (6) Disease-X mRNA Vaccine (e.g. within 100 days). Normax mission is to deliver competitive financial performance with transformative social impact. NOT AN OFFER TO INVEST.

STATISTICS AND SAFETY. 13.26 billion Coronavirus (COVID-19) Vaccinations. (668 million in U.S.) COVID-19 Vaccine Safety Surveillance - FDA and CDC

STATISTICS AND SAFETY. 13.26 billion Coronavirus (COVID-19) Vaccinations. (668 million in U.S.) COVID-19 Vaccine Safety Surveillance – FDA and CDC

Coronavirus (COVID-19) Vaccinations – Our World in Data

69.4% of the world population has received at least one dose of a COVID-19 vaccine.
13.26 billion doses have been administered globally, and 1.27 million are now administered each day.
26.4% of people in low-income countries have received at least one dose.

COVID-19 Vaccine Safety Surveillance – FDA

Summaries of Monitoring Efforts

FDA is conducting intensive monitoring of COVID-19 vaccine safety in the U.S. using a variety of approaches. Based on available information, FDA strongly believes that the known and potential benefits of COVID-19 vaccination greatly outweigh their known and potential risks. As part of our efforts to be transparent about our COVID-19 vaccine safety monitoring activities, FDA is posting summaries of the key safety monitoring findings on this page.

Hundreds of Millions of People Have Safely Received a COVID-19 Vaccine – CDC

More than 668 million doses of COVID-19 vaccine have been given in the United States from December 14, 2020, through January 26, 2023. To view the current total number of COVID-19 vaccinations that have been administered in the United States, please visit the CDC COVID Data Tracker.

COVID-19 vaccines are safe and effective. COVID-19 vaccines were evaluated in tens of thousands of participants in clinical trials. The vaccines met the Food and Drug Administration’s (FDA’s) rigorous scientific standards for safety, effectiveness, and manufacturing quality needed to support emergency use authorization (EUA). Learn more about EUAs in this video.

The Pfizer-BioNTech, Moderna, and Johnson & Johnson/Janssen and Novavax COVID-19 vaccines will continue to undergo the most intensive safety monitoring in US history. This monitoring includes using both established and new safety monitoring systems to make sure that COVID-19 vaccines are safe.

Common Side Effects

Some people have side effects after getting their COVID-19 vaccine, while others might have no side effects. Side effects may affect the ability to do daily activities, but they should go away within a few days. Learn more about common side effects after COVID-19 vaccination.

Adverse Events (Serious Safety Problems) Are Rare

In rare cases, people have experienced serious health events after COVID-19 vaccination. Any health problem that happens after vaccination is considered an adverse event. An adverse event can be caused by the vaccine or can be caused by a coincidental event not related to the vaccine, such as an unrelated fever, that happened following vaccination.

To date, the systems in place to monitor the safety of these vaccines have found four serious types of adverse events following COVID-19 vaccination, with evidence that suggests, although rare, a link to certain types of COVID-19 vaccinations that were administered. They are:

Anaphylaxis

Anaphylaxis is a severe type of allergic reaction with symptoms such as hives, difficulty breathing, low blood pressure, or significant swelling of the tongue or lips. Anaphylaxis after COVID-19 vaccination is rare. Learn more about COVID-19 vaccines and allergic reactions, including anaphylaxis.

Thrombosis with Thrombocytopenia Syndrome (TTS)

Thrombosis with thrombocytopenia syndrome (TTS) is a rare but serious adverse event that causes blood clots or issues with clotting. TTS after COVID-19 vaccination is rare. Learn more about COVID-19 vaccines and adverse events, including TTS.

Myocarditis and Pericarditis

Myocarditis is inflammation of the heart muscle, and pericarditis is inflammation of the outer lining of the heart. Myocarditis and pericarditis after COVID-19 vaccination are rare. Learn more about COVID-19 vaccines and adverse events, including myocarditis and pericarditis.

Guillain-Barré Syndrome (GBS)

Guillain-Barré Syndrome (GBS) is a rare disorder where the body’s immune system damages nerve cells, causing muscle weakness and sometimes paralysis. GBS after COVID-19 vaccination is rare. Learn more about COVID-19 vaccines and adverse events, including GBS.

Reports of Death Are Rare

Reports of death after COVID-19 vaccination are rare. FDA requires healthcare providers to report any death after COVID-19 vaccination to the Vaccine Adverse Event Reporting System (VAERS), even if it’s unclear whether the vaccine was the cause. Reports of adverse events to VAERS following vaccination, including deaths, do not necessarily mean that a vaccine caused a health problem. CDC and FDA review reports of death following COVID-19 vaccination and update information as it becomes available. Learn more about adverse events, including reports of death, after COVID-19 vaccination.

Benefits of Vaccination Outweigh the Risks

Serious side effects that could cause a long-term health problem are extremely rare following any vaccination, including COVID-19 vaccination. The benefits of COVID-19 vaccination outweigh the known and potential risks.

CDC continues to closely monitor the safety of COVID-19 vaccines. Everyone who receives a COVID-19 vaccine can also participate in safety monitoring by enrolling themselves -or their children or dependents 6 months and older in a smartphone-based system called v-safe and completing health check-ins after COVID-19 vaccination.

Have you experienced a side effect following COVID-19 vaccination?

Please report it to VAERS. In addition, enrolling yourself or your dependent in v-safe allows you to easily report to CDC how you are feeling after getting a COVID-19 vaccine.

More Information

The Vaccine Adverse Event Reporting System (VAERS)

DISCLAIMER EXAMPLE…

The Vaccine Adverse Event Reporting System (VAERS)

The Vaccine Adverse Event Reporting System (VAERS) database contains information on unverified reports of adverse events (illnesses, health problems and/or symptoms) following immunization with US-licensed vaccines. Reports are accepted from anyone and can be submitted electronically at www.vaers.hhs.gov.

EXAMPLE…

Search Current VAERS Data

The information in this database contains reports received from 1990 to the present. Data can be searched by the following: age, event category, gender, manufacturers, onset interval, recovery status, serious/non-serious category, state/territory, symptoms, vaccine, VAERS ID #, year reported, month reported, year vaccinated and month vaccinated. Click the VAERS Data Search button below to begin your data search.

* This allows you to search for details on a specific VAERS report by the VAERS ID number.

How to Access Data from CDC’s VAERS WONDER System

Written steps: How to access VAERS data

Video: How to access VAERS data

This video demonstrates how to search VAERS data using CDC WONDER. You will also learn about the purpose of VAERS and strengths and limitations of VAERS data.

Watch specific sections of the video:

Learn More

This website includes “forward-looking statements” within the meaning of the “safe harbor” provisions of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the use of words such as “forecast,” “intend,” “seek,” “target,” “anticipate,” “believe,” “will,” “expect,” “estimate,” “plan,” “outlook,” and “project” and other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. Such forward-looking statements include statements about our beliefs and expectations and the estimated financial information and other projections contained herein. Such forward-looking statements with respect to revenues, earnings, performance, strategies, prospects and other aspects of the businesses of Normax Biomed Ltd. are based on current expectations that are subject to risks and uncertainties. A number of factors could cause actual results or outcomes to differ materially from those expressed or implied by such forward-looking statements. Please refer to the final prospectus of Normax Biomed Limited under “Risk Factors” therein, and other documents filed or to be filed with the London Stock Exchange and the Swiss Stock Exchange (SIX) by Normax Biomed Ltd. You are cautioned not to place undue reliance upon any forward-looking statements, which speak only as of the date made. Normax Biomed Ltd. undertakes no commitment to update or revise the forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

The information on this website shall not constitute a solicitation of a proxy, consent or authorization with respect to any securities or in respect of the proposed transaction. The information on this website shall also not constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of securities in any states or jurisdictions in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. No offering of securities shall be made except by means of a prospectus meeting the listing requirements of the London Stock Exchange and the Swiss Stock Exchange (SIX).

This website is directed only at, and provides information about products and services only available to, those who are Professional Clients or Eligible Counterparties as defined by the Financial Conduct Authority. The definitions can be found on the FCA website at www.fca.org.uk. This website is not intended to be accessed by any persons or entities domiciled in any jurisdiction where being treated as the types of clients stated would be contrary to local law.